Basic Information
Vedrop
Regulatory Information
EMEA/H/C/000920
July 23, 2009
14
December 16, 2024
Company Information
France
Immeuble le Wilson 70, avenue du Général de Gaulle 92800 Puteaux
RECORDATI RARE DISEASES
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Vedrop is indicated in vitamin-E deficiency due to digestive malabsorption in paediatric patients suffering from congenital chronic cholestasis or hereditary chronic cholestasis, from birth (in term newborns) to 16 or 18 years of age, depending on the region.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Vedrop. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Vedrop. For practical information about using Vedrop, patients should read the package leaflet or contact their doctor or pharmacist.